Nomination for collaboration to develop novel protein expression technology to enhance manufacture of vital biotherapeutics
New York, NY, USA and Chalfont St Giles, UK – 3 October 2014 – Promosome LLC and GE Healthcare Life Sciences, (NYSE: GE), announced today that the companies’ collaboration to develop and bring to market Promosome’s innovative cell line development technologies for increasing expression levels for hard-to-manufacture proteins has been shortlisted for a leading industry award.
John Manzello, President and CEO of Promosome, said: "The BioProcess International (BPI) Awards are voted for by experts in the field to acknowledge excellence in people, organizations and technologies and we are proud to have been shortlisted along with GE Healthcare for our joint collaboration."
Morgan Norris, General Manager for Upstream Products, BioProcess, GE Healthcare Life Sciences, said: "Our vision is to help the biopharmaceutical industry bring better products to market more quickly and at lower cost. The industry is constantly looking for ways to improve efficiency, and Promosome’s technologies provide a powerful way to drive up protein yields as well as boost the output of cell lines for hard-to-express proteins. Being shortlisted with Promosome for the Most Effective Licensing or Comarketing Agreement is a great honour and a terrific endorsement by our industry peers." The agreement grants GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
- ENDS -
Notes To Editors
About Promosome
Promosome is a synthetic biology company founded to commercialize the discoveries of Nobel Laureate, Dr. Gerald M. Edelman, and colleague Dr. Vincent P. Mauro of The Scripps Research Institute (TSRI) in La Jolla, California. Leveraging Drs. Edelman and Mauro's unparalleled expertise in the areas of mRNA translation, Promosome offers licensing opportunities on these technical advances for biotherapeutic and bioindustrial companies seeking to improve expression efficiencies. The company has recently established its developmental facility in La Jolla to initiate a pipeline of its own proprietary proteins incorporating these mRNA translation based advances.
For more information on Promosome's technology and Promosome corporate information, please visit http://www.promosome.com/.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Each company accepts responsibility for the accuracy of statements relating to their respective operations. Issued for and on behalf of Promosome and GE Healthcare Life Sciences by Instinctif Partners.
For more information please contact:
Media Contact:
Promosome
John F. Manzello, CEO
T +1- 858 622-1026
E jmanzello@promosome.com
GE Healthcare
Dr Val Jones, Media Relations Manager
T +44 7917 175 192
E val.jones@ge.com
@GEHealthcare
Help employers find you! Check out all the jobs and post your resume.
New York, NY, USA and Chalfont St Giles, UK – 3 October 2014 – Promosome LLC and GE Healthcare Life Sciences, (NYSE: GE), announced today that the companies’ collaboration to develop and bring to market Promosome’s innovative cell line development technologies for increasing expression levels for hard-to-manufacture proteins has been shortlisted for a leading industry award.
John Manzello, President and CEO of Promosome, said: "The BioProcess International (BPI) Awards are voted for by experts in the field to acknowledge excellence in people, organizations and technologies and we are proud to have been shortlisted along with GE Healthcare for our joint collaboration."
Morgan Norris, General Manager for Upstream Products, BioProcess, GE Healthcare Life Sciences, said: "Our vision is to help the biopharmaceutical industry bring better products to market more quickly and at lower cost. The industry is constantly looking for ways to improve efficiency, and Promosome’s technologies provide a powerful way to drive up protein yields as well as boost the output of cell lines for hard-to-express proteins. Being shortlisted with Promosome for the Most Effective Licensing or Comarketing Agreement is a great honour and a terrific endorsement by our industry peers." The agreement grants GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
- ENDS -
Notes To Editors
About Promosome
Promosome is a synthetic biology company founded to commercialize the discoveries of Nobel Laureate, Dr. Gerald M. Edelman, and colleague Dr. Vincent P. Mauro of The Scripps Research Institute (TSRI) in La Jolla, California. Leveraging Drs. Edelman and Mauro's unparalleled expertise in the areas of mRNA translation, Promosome offers licensing opportunities on these technical advances for biotherapeutic and bioindustrial companies seeking to improve expression efficiencies. The company has recently established its developmental facility in La Jolla to initiate a pipeline of its own proprietary proteins incorporating these mRNA translation based advances.
For more information on Promosome's technology and Promosome corporate information, please visit http://www.promosome.com/.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
Each company accepts responsibility for the accuracy of statements relating to their respective operations. Issued for and on behalf of Promosome and GE Healthcare Life Sciences by Instinctif Partners.
For more information please contact:
Media Contact:
Promosome
John F. Manzello, CEO
T +1- 858 622-1026
E jmanzello@promosome.com
GE Healthcare
Dr Val Jones, Media Relations Manager
T +44 7917 175 192
E val.jones@ge.com
@GEHealthcare
Help employers find you! Check out all the jobs and post your resume.
